Aevi Genomic Medicine Inc (GNMX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Aevi Genomic Medicine Inc (GNMX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6481
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamatergic neuromodulator, which is in Phase II and III SAGA trial for adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network. Aevi’s product candidate AEVI-002, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. It collaborates with other research institutes and companies. Aevi is headquartered in Wayne, Pennsylvania, the US.

Aevi Genomic Medicine Inc (GNMX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Aevi Genomic Medicine Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Aevi Genomic Medicine Inc, Medical Equipment, Deal Details 10
Equity Offering 10
Aevi Genomic Medicine Plans to Raise up to USD20 Million in Public Offering of Shares 10
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 11
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 12
Medgenics Raises USD24.2 Million in Public Offering of Shares 13
Aevi Genomic Medicine Inc – Key Competitors 15
Aevi Genomic Medicine Inc – Key Employees 16
Aevi Genomic Medicine Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 02, 2018: Aevi Genomic Medicine reports second quarter 2018 financial results and provides business update 18
May 15, 2018: Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update 20
Mar 13, 2018: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 21
Nov 02, 2017: Aevi Genomic Medicine Reports Third Quarter 2017 Financial Results 22
May 10, 2017: Aevi Genomic Medicine Announces First Quarter 2017 Operating Results 23
Mar 09, 2017: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 24
Corporate Communications 26
Dec 04, 2017: Aevi Genomic Medicine Announces New Appointment to its Board of Directors 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Aevi Genomic Medicine Inc, Medical Equipment, Key Facts, 2017 2
Aevi Genomic Medicine Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Aevi Genomic Medicine Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Deals By Market, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Aevi Genomic Medicine Plans to Raise up to USD20 Million in Public Offering of Shares 10
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 11
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 12
Medgenics Raises USD24.2 Million in Public Offering of Shares 13
Aevi Genomic Medicine Inc, Key Competitors 15
Aevi Genomic Medicine Inc, Key Employees 16
Aevi Genomic Medicine Inc, Subsidiaries 17

List of Figures
Aevi Genomic Medicine Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Aevi Genomic Medicine Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Aevi Genomic Medicine Inc (GNMX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT. Bank Rakyat Indonesia (Persero) Tbk.:戦略・SWOT・企業財務分析
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • FGL Sports Ltd. :企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • B3 S.A.
    B3 S.A. - Strategy, SWOT and Corporate Finance Report Summary B3 S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Bird Rock Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators and therapeutic antiobodies. The company’s pipeline products include RYI-018, Gerilimzumab and Namacizumab. Its RYI-018 is a peripheral antagonist …
  • Malayan Flour Mills Berhad:戦略・SWOT・企業財務分析
    Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report Summary Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lyft Inc (LYFT):企業の財務・戦略的SWOT分析
    Lyft Inc (LYFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Shinva Medical Instrument Co Ltd (600587)-医療機器分野:企業M&A・提携分析
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s products portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instru …
  • Central Rand Gold Ltd:企業の戦略・SWOT・財務情報
    Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Arizona Public Service Co:電力:M&Aディール及び事業提携情報
    Summary Arizona Public Service Co (APS), a subsidiary of Pinnacle West Capital Corporation, is an energy utility that generates, procures, transmits, and distributes electricity. The company generates electricity from coal, nuclear, gas, oil, and renewable sources such as solar, wind, geothermal, bi …
  • Heidelberger Druckmaschinen AG (HDD):企業の財務・戦略的SWOT分析
    Heidelberger Druckmaschinen AG (HDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Commercial Bank of Dubai PSC:企業の戦略・SWOT・財務情報
    Commercial Bank of Dubai PSC - Strategy, SWOT and Corporate Finance Report Summary Commercial Bank of Dubai PSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sectra AB (SECT B)
    Sectra AB (SECT B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Pfizer Inc.:企業のM&A・事業提携・投資動向
    Pfizer Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pfizer Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Salt Lake Potash Ltd (SO4):企業の財務・戦略的SWOT分析
    Summary Salt Lake Potash Ltd (Salt Lake Potash), formerly Wildhorse Energy Ltd, is a mining and mineral exploration and development company that develops and evaluates underground coal gasification projects and uranium deposits. The company operates exploration and mining activities with geographic …
  • Virgin Australia Holdings Limited:企業のM&A・事業提携・投資動向
    Virgin Australia Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Virgin Australia Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報
    Summary Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. …
  • G4S plc:企業の戦略・SWOT・財務情報
    G4S plc - Strategy, SWOT and Corporate Finance Report Summary G4S plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Magnitogorsk Metallurgicheskiy Kombinat:企業の戦略・SWOT・財務情報
    Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report Summary Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Groupe Le Duff S.A.(Foodservice):企業の戦略・SWOT・財務情報
    Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Eurofarma Laboratorios SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofarma Laboratorios SA (Eurofarma), formerly Bill Farmaceutica is a pharmaceutical company that manufactures and markets prescription, generic and veterinary drugs. The company offers prescription products such as aerosol ointment, alprazolam, acebrophylline, altiva, ebastel, fluoruracila …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆